Kezar Life Sciences (NASDAQ:KZR) Receives Market Perform Rating from William Blair

William Blair restated their market perform rating on shares of Kezar Life Sciences (NASDAQ:KZR) in a report issued on Wednesday morning,RTT News reports.

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Kezar Life Sciences in a research report on Monday, October 14th.

Kezar Life Sciences Trading Down 0.8 %

NASDAQ KZR opened at $7.46 on Wednesday. Kezar Life Sciences has a 12-month low of $5.20 and a 12-month high of $11.35. The company has a quick ratio of 9.58, a current ratio of 7.65 and a debt-to-equity ratio of 0.05. The company has a fifty day simple moving average of $7.20 and a two-hundred day simple moving average of $6.83.

Kezar Life Sciences (NASDAQ:KZR) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($2.78) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.03) by $0.25. On average, equities research analysts expect that Kezar Life Sciences will post -6.47 earnings per share for the current year.

Institutional Trading of Kezar Life Sciences

A number of hedge funds have recently added to or reduced their stakes in KZR. Geode Capital Management LLC increased its stake in shares of Kezar Life Sciences by 15.0% during the third quarter. Geode Capital Management LLC now owns 626,912 shares of the company’s stock worth $485,000 after purchasing an additional 81,678 shares in the last quarter. XTX Topco Ltd grew its stake in shares of Kezar Life Sciences by 256.1% in the 3rd quarter. XTX Topco Ltd now owns 52,148 shares of the company’s stock valued at $40,000 after buying an additional 37,504 shares during the period. Ikarian Capital LLC lifted its stake in shares of Kezar Life Sciences by 23.0% in the 3rd quarter. Ikarian Capital LLC now owns 1,068,992 shares of the company’s stock valued at $827,000 after purchasing an additional 200,000 shares during the last quarter. Stonepine Capital Management LLC increased its position in shares of Kezar Life Sciences by 42.0% during the third quarter. Stonepine Capital Management LLC now owns 1,491,305 shares of the company’s stock valued at $1,153,000 after acquiring an additional 440,853 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in Kezar Life Sciences during the 2nd quarter valued at about $63,000. 67.90% of the stock is owned by hedge funds and other institutional investors.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.